“As Science noted in its story on the retracted paper, scientists are still debating whether the amyloid theory is viable. The skeptics cite the fraudulent research and lack of a genuine breakthrough; supporters can point to this new class of drugs including donanemab that have led to some improvement in some patients.”
https://www.vox.com/future-perfect/355108/alzheimers-disease-drug-approval-research-retraction
“Last week, a panel of independent advisers to the FDA unanimously voted in support of Eli Lilly’s donanemab, a competitor in the same class of drugs that target amyloid plaques in the brain. The FDA is expected to decide on whether to approve the drug by the end of the year.
Life expectancies around the world have surged in recent decades, increasingly putting people at risk of dementia. About one in nine seniors has Alzheimer’s disease, the most common cause of the condition, which works out to some seven million Americans.”
https://finance.yahoo.com/news/two-better-one-alzheimer-market-110000384.html
“The long-awaited era of disease-modifying therapy for Alzheimer’s disease has finally arrived and will substantially impact how the disease is perceived and managed, although these new treatments will pose challenges for equitable access. The drugs closest to widespread clinical implementation are lecanemab and donanemab—intravenous monoclonal antibodies that remove β-amyloid plaques from the brain and can slow cognitive and functional decline.”
Donanemab appears to be the ‘easier’ choice. MMSE 20-28, Monthly Infusion (vs q2Wk), Stop when Amyloid PET is negative. Probably need to get APOE on these patients.
https://doi.org/10.1016/S1474-4422(23)00274-0
Contact Dr. Varipapa’s office if you are interested in exploring this option.
CNMRI: Neurology, Sleep Medicine, MRI 